Advice

in the absence of a submission from the holder of the marketing authorisation:

daratumumab (Darzalex®) is not recommended for use within NHSScotland.

Indication under review: In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice612KB (PDF)

Download

Medicine details

Medicine name:
daratumumab (Darzalex)
SMC ID:
SMC2269
Indication:

In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Eye
Submission type
Non submission
Status
Not recommended
Date advice published
10 February 2020